Morningside Venture, a private equity firm, and J. Wood Capital Advisors, a broker-dealer, completed the acquisition of Stealth BioTherapeutics, a clinical-stage biotechnology company. Financial terms were not disclosed. Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging. The team works with patients and advocacy organizations to better understand their journey with mitochondrial disease and raise awareness of the unmet need our programs seek to address.